Apogee Therapeutics climbs as APG777 52-week Phase 2 data keeps bid strong
Apogee Therapeutics (APGE) shares are higher on April 9, 2026 as investors continue to react to late-March positive 52-week Phase 2 data for its atopic dermatitis drug candidate zumilokibart (APG777). The move also comes after the company priced a $350 million public offering at $70.00 per share that closed March 26, strengthening its cash position for upcoming trials.
1) What’s moving APGE today
Apogee Therapeutics is trading higher today as the market continues to price in the company’s late-March clinical update showing positive 52-week maintenance data from Part A of the Phase 2 APEX trial for zumilokibart (APG777) in moderate-to-severe atopic dermatitis, highlighting sustained responses with dosing every 3 or 6 months. The stock’s strength follows the company’s March financing event, which improved the near-term funding outlook and can support upcoming development work as additional data approach. (investors.apogeetherapeutics.com)
2) Why investors are focused on the APG777 data
The March 23 update emphasized durability of response through 52 weeks and positioned APG777 around a less-frequent dosing strategy relative to current standards of care, a key commercial and adherence angle in inflammatory dermatology. The company also framed APEX Part B 16-week induction data as an upcoming catalyst expected in the second quarter of 2026, which is important for dose selection and Phase 3 planning. (investors.apogeetherapeutics.com)
3) Capital raise backdrop: $350 million priced at $70
Apogee priced an underwritten public offering of 5,000,000 shares at $70.00 per share for expected gross proceeds of about $350 million, with an option for underwriters to purchase up to an additional 750,000 shares. The company said the offering was expected to close on March 26, 2026, giving investors added confidence in balance-sheet runway as it advances multiple immunology and inflammation programs. (investors.apogeetherapeutics.com)
4) What to watch next
Near-term attention centers on the APEX Part B 16-week readout expected in Q2 2026 and any updates on Phase 3 timing for atopic dermatitis in the second half of 2026. Investors are also monitoring whether management provides incremental clarity through updated decks and conference materials following the March 29 corporate presentation refresh. (investors.apogeetherapeutics.com)